With Flu Shot Vote, Kennedy's Vaccine Skepticism Comes Full Circle
The book, published in 2014, explored an obscure mercury-based preservative, thimerosal, that was removed from most vaccines, but not flu vaccines, more than two decades ago. Dr. Oz noted that the Centers for Disease Control and Prevention had deemed the vaccines that still contained thimerosal 'safe and effective' and said they did 'not present a public health risk.'
Mr. Kennedy did not buy it. 'We found 500 peer-reviewed studies,' he insisted. 'Virtually every one of them said that thimerosal is a potent neurotoxin that should not be in vaccines.'
On Thursday, the new members of the C.D.C.'s Advisory Committee on Immunization Practices, hand-selected by Mr. Kennedy after he fired all 17 members of the previous panel, decided it would longer recommend annual flu shots that contain it. Thimerosal's appearance on the committee's agenda in the first place shocked public health leaders, who have long considered the matter settled.
But it was not a surprise to people who have followed Mr. Kennedy closely. Thimerosal started Mr. Kennedy down a path of questioning vaccine safety, and Thursday's vote was the culmination of a long personal journey. It offers a window into how, as secretary, he is pursuing his own passions and installing old allies in positions of influence.
Want all of The Times? Subscribe.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
9 hours ago
- Yahoo
Primus Sounds Alarm on Chronic Venous Insufficiency as President Trump's Diagnosis Sparks National Focus
SCOTTSDALE, ARIZONA / / July 24, 2025 / Following reports of President Donald J. Trump's diagnosis with Chronic Venous Insufficiency (CVI), Primus Pharmaceuticals, Inc. strongly calls on healthcare providers to intensify efforts to diagnose and treat this silent epidemic affecting 25-30 million Americans because only less than <10% are actually treated. Leg swelling, heaviness, and varicose veins are often dismissed as cosmetic or "normal aging," while they can signal a dangerous progression toward severe complications including thromboembolism (blood clots), debilitating pain, non-healing leg ulcers, and compromised mobility. Widespread, Under-Recognized Health Threat CVI, also known as chronic venous disease or venous reflux disease, impacts twice (2x) as many Americans as coronary heart disease, three times (3x) peripheral arterial disease, and 30 times (30x) the number of Americans who have a heart attack each year. According to CDC, up to 900,000 Americans are affected by venous thromboembolism annually, and 60,000 to 100,000 people die each year. Millions suffer daily challenges - standing, sitting, flying - due to blood pooling in the legs, worsened by inactivity or pressure. Traditional treatments - leg elevation, compression stockings or surgical procedures - are often cumbersome, uncomfortable, underutilized, and may be expensive with added health risks. Life-Changing Solution: Vasculera® Primus offers Vasculera, the only U.S. prescription product for CVI. It is specifically formulated as a medical food for the clinical dietary management of CVI. Taken once daily, this 600mg tablet delivers highly purified, bioavailable diosmin, a flavonoid sourced from oranges, in combination with a pH buffering agent and: Calms inflammation and oxidative stress Strengthens weakened vein walls Improves overall venous function Counters localized CVI blood acidosis Manufactured in the U.S., Vasculera presents a novel naturally-derived alternative to the status quo. Expert Physician Perspectives "CVI and its manifestation in skin known as stasis dermatitis is a very common condition that can lead to significant impairment and morbidity," said Dr. Mark Nestor, MD, PhD, Board-certified Dermatologist and Voluntary Professor, Department of Dermatology and Cutaneous Surgery, University of Miami, Miller School of Medicine. "Diosmin in its bioavailable form in the pharmaceutical-grade medical food Vasculera is a natural flavonoid that has scientifically proven benefit for this condition." Board-certified Vascular Surgeon Dr. Ron Bush, MD, FACS, one of the world's foremost experts in the histology and treatment of venous disease states, "CVI is a common condition, with symptoms that may vary but are consistently linked to elevated venous pressure. In my clinical experience, Vasculera has proven to be an effective treatment option. Its active ingredient, diosmin, is well-studied and widely documented for its ability to address the inflammation associated with chronic venous hypertension. Vasculera is also well-tolerated and has no significant contraindications." Robust Clinical Backing Over 60 published peer-reviewed clinical studies confirm diosmin's effectiveness in reducing leg pain, swelling, and skin deterioration associated with CVI. Vascular medicine experts recommend Vasculera's ultra-micronized diosmin as the only U.S. product for venous ulcers and CVI symptoms, both as standalone and adjunctive therapy in national treatment guidelines. Public Health Call to Action With an aging population and more time on electronic devices fueling CVI's prevalence, Primus urges clinicians to: Proactively screen all at-risk patients for CVI Integrate proven prescription metabolic therapies like Vasculera with CVI standards of care For prescribing information, visit About Primus Pharmaceuticals Primus innovates in prescription nutritional therapies targeting metabolic causes of chronic diseases across rheumatology, dermatology, and women's health. We develop and commercialize first-in-class products and novel deliveries in Rx drugs, medical foods, and medical devices to fill key unmet needs with universal patient access not provided by traditional pharma. Visit Contact Information Randy Keating Public Relations Managerrkeating@ SOURCE: Primus Pharmaceuticals View the original press release on ACCESS Newswire Sign in to access your portfolio
CBS News
14 hours ago
- CBS News
Third human case of West Nile virus in Illinois reported in DuPage County
A Third human case of West Nile virus in Illinois has been reported, this time in DuPage County. The DuPage County Health Department confirmed the case on Thursday. The department said the individual is a Glen Ellyn resident in their 50s, and the onset of symptoms was mid-July. The Centers for Disease Control and Prevention first confirmed in June that a person downstate, specifically in Southern Illinois, was hospitalized due to complications of the virus. The second was confirmed in Lake County on July 16. The resident was said to be in their 70s and became ill earlier in the month. Symptoms of West Nile virus While most people infected with the virus do not feel sick, about one in five will develop a fever and flu-like symptoms. Other symptoms include body aches, vomiting, diarrhea, or rash. Severe illness can occur in about one in 150 people and is most likely to occur in people over age 55 or with weakened immune systems. How to prevent it West Nile virus is spread to people from infected mosquitoes, most commonly in the summer. Eight out of 10 people infected do not develop symptoms, according to the CDC. Residents are also reminded to practice the three "R's"– reduce the number of mosquitoes and remove containers outside that hold water, repel mosquitoes by using insect repellent, and report areas where water sits for more than a week. There are no medications to treat the virus. The only way to combat the virus is to prevent mosquito bites.
Fast Company
15 hours ago
- Fast Company
Trump rollback on clean energy subsidies stalls major solar, wind projects and manufacturing plans
Singapore-based solar panel manufacturer Bila Solar is suspending plans to double capacity at its new factory in Indianapolis. Canadian rival Heliene's plans for a solar cell facility in Minnesota are under review. Norwegian solar wafer maker NorSun is evaluating whether to move forward with a planned factory in Tulsa, Oklahoma. And two fully permitted offshore wind farms in the U.S. Northeast may never get built. These are among the major clean energy investments now in question after Republicans agreed earlier this month to quickly end U.S. subsidies for solar and wind power as part of their budget megabill, and as the White House directed agencies to tighten the rules on who can claim the incentives that remain. This marks a policy U-turn since President Donald Trump's return to office that project developers, manufacturers and analysts say will slash installations of renewable energy over the coming decade, kill investment and jobs in the clean energy manufacturing sector supporting them, and worsen a looming U.S. power supply crunch as energy-hungry AI infrastructure expands. Solar and wind installations could be 17% and 20% lower than previously forecast over the next decade because of the moves, according to research firm Wood Mackenzie, which warned that a dearth of new supplies could slow the expansion of data centers needed to support AI technology. Energy researcher Rhodium, meanwhile, said the law puts at risk $263 billion of wind, solar, and storage facilities and $110 billion of announced manufacturing investment supporting them. It will also increase industrial energy costs by up to $11 billion in 2035, it said. 'One of the administration's stated goals was to bring costs down, and as we demonstrated, this bill doesn't do that,' said Ben King, a director in Rhodium's energy and climate practice. He added the policy 'is not a recipe for continued dominance of the U.S. AI industry.' The White House did not respond to a request for comment. The Trump administration has defended its moves to end support for clean energy by arguing the rapid adoption of solar and wind power has created instability in the grid and raised consumer prices – assertions that are contested by the industry and which do not bear out in renewables-heavy power grids, like Texas' ERCOT. Power industry representatives, however, have said all new generation projects need to be encouraged to meet rising U.S. demand, including both those driven by renewables and fossil fuels. Consulting firm ICF projects that U.S. electricity demand will grow by 25% by 2030, driven by increased AI and cloud computing – a major challenge for the power industry after decades of stagnation. The REPEAT Project, a collaboration between Princeton University and Evolved Energy Research, projects a 2% annual increase in electricity demand. With a restricted pipeline of renewables, tighter electricity supplies stemming from the policy shift could increase household electricity costs by $280 a year in 2035, according to the REPEAT Project. The key provision in the new law is the accelerated phase-out of 30% tax credits for wind and solar projects: it requires projects to begin construction within a year or enter service by the end of 2027 to qualify for the credits. Previously the credits were available through 2032. Now some project developers are scrambling to get projects done while the U.S. incentives are still accessible. But even that strategy has become risky, developers said. Days after signing the law, Trump directed the Treasury Department to review the definition of 'beginning of construction.' A revision to those rules could overturn a long-standing practice giving developers four years to claim tax credits after spending just 5% of project costs. Treasury was given 45 days to draft new rules. 'With so many moving parts, financing of projects, financing of manufacturing is difficult, if not impossible,' said Martin Pochtaruk, CEO of Heliene. 'You are looking to see what is the next baseball bat that's going to hit you on the head.' About face Heliene's planned cell factory, which could cost as much as $350 million, depending on the capacity, and employ more than 600 workers, is also in limbo, Pochtaruk said in an interview earlier this month. The company needs more clarity on both what the new law will mean for U.S. demand, and how Trump's trade policy will impact the solar industry. 'We have a building that is anxiously waiting for us to make a decision,' Pochtaruk said. Similarly, Mick McDaniel, general manager of Bila Solar, said 'a troubling level of uncertainty' has put on hold its $20 million expansion at an Indianapolis factory it opened this year that would create an additional 75 jobs. 'NorSun is still digesting the new legislation and recent executive order to determine the impact to the overall domestic solar manufacturing landscape,' said Todd Templeton, director of the company's U.S. division that is reviewing plans for its $620 million solar wafer facility in Tulsa. Five solar manufacturing companies – T1 Energy, Imperial Star Solar, SEG Solar, Solx and ES Foundry – said they are also concerned about the new law's impact on future demand, but that they have not changed their investment plans. The policy changes have also injected fresh doubt about the fate of the nation's pipeline of offshore wind projects, which depend heavily on tax credits to bring down costs. According to Wood Mackenzie, projects that have yet to start construction or make final investment decisions are unlikely to proceed. Two such projects, which are fully permitted, include a 300-megawatt project by developer US Wind off the coast of Maryland and Iberdrola's 791 MW New England Wind off the coast of Massachusetts. Neither company responded to requests for comment. 'They are effectively ready to begin construction and are now trapped in a timeline that will make it that much harder to be able to take advantage of the remaining days of the tax credits,' said Hillary Bright, executive director of offshore wind advocacy group Turn Forward.
